Shattuck Labs' Cash Balance Of Approximately $90M As Of September 30, 2024; Expected To Fund Operations Into 2027
Shattuck Labs' Cash Balance Of Approximately $90M As Of September 30, 2024; Expected To Fund Operations Into 2027
Financial Guidance
財務指導
Shattuck has effectuated its restructuring plan to prioritize the development of the DR3 program and align the Company's cost and workforce structure with the its current goals and clinical development strategy. The Company has substantially completed the reduction in force associated with the discontinuation of SL-172154.
Shattuck已經實施了重組計劃，以優先發展DR3項目，並將公司的成本和員工結構與其當前的目標和臨床開發策略對齊。公司已實質性完成與停止SL-172154相關的裁員。
Shattuck believes its cash and cash equivalents and investments will be sufficient to fund its planned operations into 2027, beyond results from its Phase 1 clinical trial of SL-325. This cash runway guidance is based on the Company's current operational plans and excludes any additional capital that may be received, proceeds from potential business development transactions, and/or additional costs associated with additional development activities that may be undertaken.
Shattuck相信其現金及現金等價物和投資將足以資助其計劃的運營，直到2027年，超過SL-325第一階段臨床試驗的結果。該現金使用指導基於公司的當前運營計劃，並不包括可能收到的任何額外資本、潛在業務開發交易的收益以及/或可能進行的額外開發活動所產生的額外成本。
譯文內容由第三人軟體翻譯。
